In vitro antiparasitic and apoptotic effects of antimony sulfide nanoparticles on leishmania infantum

Journal of Parasitology Research

Volumn 2012, Issue , 2012, Pages

  Soflaei, Saied ^a   Dalimi, Abdolhossein ^a   Ghaffarifar, Fatemeh ^a   Shakibaie, Mojtaba ^a,b   Shahverdi, Ahmad Reza ^c   Shafiepour, Mohsen ^d  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY SULFIDE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ANTIPARASITIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FLOW CYTOMETRY; IC 50; IN VITRO STUDY; LEISHMANIA INFANTUM; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SERRATIA MARCESCENS;

EID: 84864954409     PISSN: 20900023     EISSN: 20900031     Source Type: Journal    
DOI: 10.1155/2012/756568     Document Type: Article

References (41)

1. Murray H. W., Berman J. D., Davies C. R., Saravia N. G., Advances in leishmaniasis The Lancet 2005 366 9496 1561 1577 (Pubitemid 41540115)
2. Kafetzis D. A., Maltezou H. C., Visceral leishmaniasis in paediatrics Current Opinion in Infectious Diseases 2002 15 3 289 294 (Pubitemid 34548192)
3. Herwaldt B. L., Leishmaniasis The Lancet 1999 354 9185 1191 1199 (Pubitemid 29460458)
4. World Health Organization, 2002, http://www.who.int/tdr/publications/ documents/vl-rdt-evaluation.pdf
5. Maltezou H. C., Visceral leishmaniasis: advances in treatment Recent Patents on Anti-Infective Drug Discovery 2008 3 3 192 198
6. Natera S., Machuca C., Padrn-Nieves M., Romero A., Daz E., Ponte-Sucre A., Leishmania spp.: proficiency of drug-resistant parasites International Journal of Antimicrobial Agents 2007 29 6 637 642 (Pubitemid 46710356)
7. Chance M. L., New developments in the chemotherapy of leishmaniasis Annals of Tropical Medicine and Parasitology 1995 89 1 37 43 (Pubitemid 26030067)
8. Rijal S., Yardley V., Chappuis F., Decuypere S., Khanal B., Singh R., Boelaert M., De Doncker S., Croft S., Dujardin J. C., Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes and Infection 2007 9 4 529 535 (Pubitemid 46442794)
9. Loiseau P. M., Bories C., Recent strategies for the chemotherapy of visceral leishmaniasis Current Opinion in Infectious Diseases 1999 12 6 559 564 (Pubitemid 30058148)
10. Grevelin S., Lerner E., Leishmaniasis Journal of the American Academy of Dermatology 1996 34 257 272 (Pubitemid 26063997)
11. Fusai T., Durand R., Boulard Y., Paul M., Bories C., Rivollet D., Houin R., Deniau M., Importance of drug carriers in the treatment of visceral Leishmaniasis Medecine Tropicale 1995 55 1 73 78
12. Veeken H., Ritmeijer K., Seaman J., Davidson R., A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan Tropical Medicine and International Health 2000 5 5 312 317 (Pubitemid 30407866)
13. Sundar S., Sinha P. R., Agrawal N. K., Srivastava R., Rainey P. M., Berman J. D., Murray H. W., Singh V. P., A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate American Journal of Tropical Medicine and Hygiene 1998 59 1 139 143 (Pubitemid 28304811)
14. Roberts W. L., Mcmurray W. J., Rainey P. M., Characterization of the antimonial antileishmanial agent meglumine antimonate (Glucantime) Antimicrobial Agents and Chemotherapy 1998 42 5 1076 1082 (Pubitemid 28227900)
15. Barbosa da SIlva J. J., Antimoniato de meglumina The Revista da Sociedade Brasileira de Medicina Tropical 2001 34 103 105
16. Berman J., Current treatment approaches to leishmaniasis Current Opinion in Infectious Diseases 2003 16 5 397 401 (Pubitemid 37267258)
17. http://en.wikipedia.org/wiki/Nanomedicine
18. Venier-Julienne M. C., Vouldoukis I., Monjour L., Benoit J. P., In vitro study of the anti-leishmanial activity of biodegradable nanoparticles Journal of Drug Targeting 1995 3 1 23 29
19. Durand R., Paul M., Rivollet D., Fessi H., Houin R., Astier A., Deniau M., Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model Parasite 1997 4 4 331 336 (Pubitemid 127497638)
20. Rodrigues J. M., Croft S. L., Fessi H., Bories C., Devissguet J. P., The activity and ultrastructural localization of primaquine-loaded poly (D, L-lactide) nanoparticles in Leishmania donovani infected mice Tropical Medicine and Parasitology 1994 45 3 223 228 (Pubitemid 24312029)
21. Torres-Santos E. C., Rodrigues J. M., Moreira D. L., Kaplan M. A. C., Rossi-Bergmann B., Improvement of in vitro and in vivo antileishmanial activities of 2 ′, 6 ′-dihydroxy- 4 ′ -methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles Antimicrobial Agents and Chemotherapy 1999 43 7 1776 1778 (Pubitemid 29331268)
22. Durand R., Paul M., Rivollet D., Houin R., Astier A., Deniau M., Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model International Journal for Parasitology 1997 27 11 1361 1367 (Pubitemid 27502238)
23. Gaspar R., Opperdoes F. R., Preat V., Roland M., Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani Annals of Tropical Medicine and Parasitology 1992 86 1 41 49
24. Espuelas M. S., Legrand P., Loiseau P. M., Bories C., Barratt G., Irache J. M., In vitro antileishmanial activity of amphotericin B loaded in poly( -caprolactone) nanospheres Journal of Drug Targeting 2002 10 8 593 599 (Pubitemid 36124359)
25. Kayser O., Olbrich C., Yardley V., Kiderlen A. F., Croft S. L., Formulation of amphotericin B as nanosuspension for oral administration International Journal of Pharmaceutics 2003 254 1 73 75 (Pubitemid 36259814)
26. Kayser O., Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages International Journal of Pharmaceutics 2000 196 2 253 256 (Pubitemid 30105755)
27. Veera P. R., Vobalaboina V., Ali N., Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres Journal of Drug Targeting 2009 17 2 140 147
28. Bahrami K., Nazari P., Sepehrizadeh Z., Zarea B., Shahverdi A. R., Microbial synthesis of antimony sulfide nanoparticles and their characterization. Annals of Microbiology. In press
29. Tada H., Shiho O., Kuroshima K. I., An improved colorimetric assay for interleukin 2 Journal of Immunological Methods 1986 93 2 157 165 (Pubitemid 17190370)
30. Chang K. P., Dwyer D. M., Leishmania donovani. Hamster macrophage interactions in vitro: cell entry, intracellular survival, and multiplication of amastigotes Journal of Experimental Medicine 1978 147 2 515 530 (Pubitemid 8284122)
31. Pérez-Victoria F. J., Snchez-Caete M. P., Seifert K., Croft S. L., Sundar S., Castanys S., Gamarro F., Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use Drug Resistance Updates 2006 9 1-2 26 39 (Pubitemid 43928805)
32. Singh U. K., Prasad R., Mishra O. P., Jayswal B. P., Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study Indian Journal of Pediatrics 2006 73 12 1077 1080
33. Sundar S., Jha T. K., Sindermann H., Junge K., Bachmann P., Berman J., Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis Pediatric Infectious Disease Journal 2003 22 5 434 438 (Pubitemid 36578746)
34. Wyllie S., Cunningham M. L., Fairlamb A. H., Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani Journal of Biological Chemistry 2004 279 38 39925 39932 (Pubitemid 39258265)
35. Moreiera E. S. A., Petrillo-Peixoto M. L., In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes Brazilian Journal of Medical and Biological Research 1991 24 5 459 469
36. Netto E. M., Marsden P. D., Llanos-Cuentas E. A., Costa J. M. L., Cuba C. C., Barreto A. C., Badaro R., Johnson W. D., Jones T. C., Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime Transactions of the Royal Society of Tropical Medicine and Hygiene 1990 84 3 367 370 (Pubitemid 20204315)
37. Date A. A., Joshi M. D., Patravale V. B., Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles Advanced Drug Delivery Reviews 2007 59 6 505 521 (Pubitemid 47259228)
38. Gour J. K., Srivastava A., Kumar V., Bajpai S., Kumar H., Mishra M., Singh R. K., Nanomedicine and leishmaniasis: future prospects Digest Journal of Nanomaterials and Biostructures 2009 4 3 495 499
39. Owais M., Gupta C. M., Targeted drug delivery to macrophages in parasitic infections Current Drug Delivery 2005 2 4 311 318 (Pubitemid 41277764)
40. Das N., Mahato S. B., Naskar K., Ghosh D. K., Basu M. K., Targeting of urea stibamine encapsulated in liposomes to reticuloendothelial system for the treatment of experimental leishmaniasis Biochemical Medicine and Metabolic Biology 1990 43 2 133 139 (Pubitemid 20175786)
41. Espuelas S., Delivery system for the treatment and prevention of leishmaniasis Gazeta Médica da Bahia 2009 79 supplement 3 134 146